Condition: Overweight and Obesity · Sponsor: Wave Life Sciences USA, Inc.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in two adult populations: Pre Type 2 diabetes (Pre T2D) and Type 2 Diabetes (T2D) in adults who are affected by obesity.
This description comes directly from the study's public registry record.
Clinical Operations · 855-215-4687 · Clinicaltrials@wavelifesci.com
Always discuss trial participation with your own doctor first.
| Parexel International-EPCU Baltimore | Baltimore, Maryland, United States | Recruiting |
| ARENSIA Research Clinic | Chisinau, Moldova | Recruiting |
| Arensia Clinics S.R.L. | Bucharest, Romania | Recruiting |
| Spitalul Clinic Judetean De Urgenta Cluj | Cluj-Napoca, Romania | Recruiting |
| Parexel International Early Phase Clinical Unit | Harrow, United Kingdom | Recruiting |
| Simbec-Orion Clinical Pharmacology | Merthyr Tydfil, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06842186